Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sipuleucel-T

- PMLiVE

Pfizer gets FDA OK for expanded use of lung cancer drug Xalkori

First NSCLC treatment targeting the rare ROS1 mutation to be approved in the US

National Institute for Health and Care Excellence NICE logo

NICE’s rejection of Imbruvica ‘reveals appraisal process flaws’

Leukaemia charity says the cost-effectiveness body can't cope with uncertainty

- PMLiVE

New UK Cancer Drugs Fund takes shape

NICE to manage access to cancer treatments from 1 July

- PMLiVE

Pharma forms Parkinson’s disease trials consortium

Hopes to make clinical trials “smarter” through sharing of past PD trial data

- PMLiVE

Pfizer and Allergan: The challenge starts now

The Pfizer and Allergan merger is a game changer in the pharmaceutical industry, creating the biggest drug maker in the world. The complexities of reaching this landmark agreement cannot be...

- PMLiVE

Size matters?

Pfizer’s $160bn deal to acquire Allergan will challenge the new company to show that big is better

- PMLiVE

NICE wants more data on Alexion’s orphan drug Kanuma

Calls for 'robust evidence' about the costly rare disease treatment's price and benefits

The future of Pfizer(s)

Current headlines point to a frightening journey

- PMLiVE

Pfizer settles US Protonix lawsuit for $785m

US government deal covers Wyeth’s failure to pay drug rebates

- PMLiVE

FDA panel recommends first biosimilar antibody for approval

Pfizer to sell Celltrion's infliximab in the US pending FDA approval

National Institute for Health and Care Excellence NICE logo

NICE backs Repatha but rejects cholesterol rival Praluent

New draft guidance marks a U-turn on Amgen's drug but knocks back Sanofi treatment

- PMLiVE

Pfizer to form specialty drugs unit after Allergan takeover

Will merge its consumer portfolio with Allergan's ophthalmology and aesthetics brands

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links